1. Home
  2. ECCC vs CADL Comparison

ECCC vs CADL Comparison

Compare ECCC & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ECCC

Eagle Point Credit Company Inc. 6.50% Series C Term Preferred Stock due 2031

N/A

Current Price

$24.95

Market Cap

0.0

Sector

Finance

ML Signal

N/A

Logo Candel Therapeutics Inc.

CADL

Candel Therapeutics Inc.

HOLD

Current Price

$10.87

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ECCC
CADL
Founded
N/A
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
1.0B
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
ECCC
CADL
Price
$24.95
$10.87
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$19.00
AVG Volume (30 Days)
1.9K
1.1M
Earning Date
N/A
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
58.62
EPS
N/A
N/A
Revenue
N/A
$125,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$23.02
$4.35
52 Week High
$25.50
$14.00

Technical Indicators

Market Signals
Indicator
ECCC
CADL
Relative Strength Index (RSI) 48.20 41.77
Support Level $24.68 $9.40
Resistance Level $25.50 $11.36
Average True Range (ATR) 0.21 0.69
MACD -0.02 -0.28
Stochastic Oscillator 56.37 27.99

Price Performance

Historical Comparison
ECCC
CADL

About ECCC Eagle Point Credit Company Inc. 6.50% Series C Term Preferred Stock due 2031

Eagle Point Credit Co is an externally managed, non-diversified, closed-end management investment company. The Company's primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in equity and junior debt tranches of CLOs.

About CADL Candel Therapeutics Inc.

Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

Share on Social Networks: